Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | ASCO 2022: ZUMA-2, BCMA-targeting BiTEs & novel CARs in myeloma

Matthew Frigault • 3 Jun 2022
ASCO 2022
Lymphoma Mantle Cell Lymphoma Multiple Myeloma Non-Hodgkin Lymphoma Antibodies Brexucabtagene autoleucel CAR-T
ZUMA-2

Matthew Frigault, MD, Harvard Medical School, Boston, MA, highlights long-term follow-up results of ZUMA-2 (NCT02601313) which evaluated brexucabtagene autoleucel (brexu-cel) CAR-T therapy in R/R mantle cell lymphoma (MCL), new data on the use of BCMA-targeting bispecific T-cell engagers (BiTEs) in multiple myeloma as well as the use of novel CAR-T approaches in myeloma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Matthew Frigault

0:53
Follow-up from a Phase I study of CART-ddBCMA for the treatment of R/R multiple myeloma
Matthew Frigault • 10 Dec 2023
0:58
Itacitinib for the prevention of immune effector cell therapy–associated CRS
Matthew Frigault • 12 Dec 2023
Prophylaxis and management of CRS & ICANS
Bianca Santomasso et al. • 14 Apr 2023
Rapid CAR manufacture
Caron Jacobson et al. • 14 Apr 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals